Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Improved assessment of coronary artery disease in obese Patients with flurpiridaz-<sup>18</sup>F positron emission tomography myocardial perfusion imaging: A prespecified subgroup analysis of the AURORA phase 3 study.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026

Same author

Diagnostic performance of F-18 flurpiridaz in women: A sub-study of the Aurora Phase 3 trial.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026

Same author

Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.

Annals of nuclear medicine·2025

Same author

Distribution patterns of brown adipose tissue on FDG-PET/CT has age characteristics.

Annals of nuclear medicine·2025

Same author

Analysis of clinical factors associated with incomplete standard protocol <sup>177</sup>Lu-DOTATATE treatment in neuroendocrine tumor patients.

Japanese journal of radiology·2025

Same author

<sup>18</sup>F-Fluorodeoxyglucose Imaging for Assessing Cardiovascular Inflammation.

Diagnostics (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: Nov 7, 2025

Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling

Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling

Published on: October 27, 2023

Clinical Perspectives of Theranostics.

Shozo Okamoto^1,2, Tohru Shiga³, Nagara Tamaki⁴

¹Department of Radiology, Obihiro-Kosei General Hospital, Obihiro 080-0024, Japan.

Molecules (Basel, Switzerland)

|April 30, 2021

Summary

Theranostics combines nuclear imaging and targeted radionuclide therapy for cancer treatment. This approach is expanding to include new applications like alpha-radiotherapy, improving patient outcomes and overcoming resistance.

Keywords:

PET cancer prognosis radionuclide therapy theranostics

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Related Experiment Videos

Last Updated: Nov 7, 2025

Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling

Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling

Published on: October 27, 2023

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Area of Science:

Nuclear Medicine
Oncology
Precision Medicine

Background:

Theranostics integrates diagnostic and therapeutic nuclear medicine for targeted cancer treatment.
Traditional theranostics utilize radioiodine compounds for thyroid cancer and pheochromocytoma.

Purpose of the Study:

To review current and emerging theranostic applications in oncology.
To highlight advancements in radiopharmaceuticals for various cancers.
To discuss the role of imaging in monitoring treatment response.

Main Methods:

Review of traditional theranostic applications (thyroid cancer, pheochromocytoma).
Description of recent theranostic approaches (radioimmunotherapy for lymphoma, bone metastasis treatment).
Inclusion of novel radiopharmaceuticals for prostate and pancreatic cancers.

Main Results:

F-18 Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography (PET) aids in treatment monitoring and outcome prediction.
Alpha-radiotherapy demonstrates potential in overcoming resistance to beta-particle therapy.
Theranostics is increasingly integrated into clinical nuclear medicine practice.

Conclusions:

Theranostics represents a growing field in precision medicine for cancer care.
Emerging radiopharmaceuticals and therapies like alpha-radiotherapy are expanding theranostic capabilities.
The integration of diagnostic imaging and targeted therapy offers significant potential for improved cancer management.